{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:15:30Z","timestamp":1776273330104,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["Health"],"award-info":[{"award-number":["Health"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["Labour Sciences Research Grants for research on Intractable Diseases (The Research Team for Autoimmune Diseases"],"award-info":[{"award-number":["Labour Sciences Research Grants for research on Intractable Diseases (The Research Team for Autoimmune Diseases"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["A Large-scale Multi-institutional Research Committee aiming at an epidemiological survey of spondyloarthritis"],"award-info":[{"award-number":["A Large-scale Multi-institutional Research Committee aiming at an epidemiological survey of spondyloarthritis"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["creation of diagnostic criteria"],"award-info":[{"award-number":["creation of diagnostic criteria"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["development of clinical guidelines)"],"award-info":[{"award-number":["development of clinical guidelines)"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11926-022-01068-4","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:08:35Z","timestamp":1649153315000},"page":"149-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Axial Spondyloarthritis in Japan"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","volume":"38","author":"C Stolwijk","year":"2012","unstructured":"Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin North Am. 2012;38:441\u201376. https:\/\/doi.org\/10.1016\/j.rdc.2012.09.003.","journal-title":"Rheum Dis Clin North Am"},{"key":"1068_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.autrev.2018.04.002","volume":"17","author":"E Generali","year":"2018","unstructured":"Generali E, Bose T, Selmi C, Voncken JW, Damoiseaux JGMC. Nature versus nurture in the spectrum of rheumatic diseases: classification of spondyloarthritis as autoimmune or autoinflammatory. Autoimmun Rev. 2018;17:935\u201341. https:\/\/doi.org\/10.1016\/j.autrev.2018.04.002.","journal-title":"Autoimmun Rev"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00002281-199807000-00001","volume":"10","author":"MA Khan","year":"1998","unstructured":"Khan MA. Editorial overview: Spondyloarthropathies. Curr Opin Rheumatol. 1998;10:279\u201381.","journal-title":"Curr Opin Rheumatol"},{"key":"1068_CR4","unstructured":"Tanaka H, Akaza T, Juji T. Report of the Japanese central bone marrow data center. Clin Transpl. 1996;139\u201344"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/art.1780381120","volume":"38","author":"A Yamaguchi","year":"1995","unstructured":"Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, et al. Association of Hla-B39 with Hla-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum. 1995;38:1672\u20137. https:\/\/doi.org\/10.1002\/art.1780381120.","journal-title":"Arthritis Rheum."},{"key":"1068_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/1529-0131(199801)41:1<68::AID-ART9>3.0.CO;2-C","volume":"41","author":"N Tsuchiya","year":"1998","unstructured":"Tsuchiya N, Shiota M, Moriyama S, Ogawa A, Komatsu-Wakui M, Mitsui H, et al. MICA allele typing of HLA-B27 positive Japanese patients with seronegative spondylarthropathies and healthy individuals: differential linkage disequilibrium with HLA-B27 subtypes. Arthritis Rheum. 1998;41:68\u201373. https:\/\/doi.org\/10.1002\/1529-0131(199801)41:1%3c68::AID-ART9%3e3.0.CO;2-C.","journal-title":"Arthritis Rheum"},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.2003.011247","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63:535\u201343. https:\/\/doi.org\/10.1136\/ard.2003.011247.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1068_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000053","volume":"1","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1(Suppl 1): e000053. https:\/\/doi.org\/10.1136\/rmdopen-2015-000053.","journal-title":"RMD Open"},{"key":"1068_CR9","first-page":"263","volume":"36","author":"R Bohn","year":"2018","unstructured":"Bohn R, Cooney M, Deodhar A, Curtis JR, Golembesky A. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol. 2018;36:263\u201374.","journal-title":"Clin Exp Rheumatol"},{"key":"1068_CR10","doi-asserted-by":"publisher","unstructured":"\u2022 Bittar M, Yong WC, Magrey M, Khan MA. Worldwide differences in clinical phenotype of axial spondyloarthritis. Curr Rheumatol Rep. 2021;23:76. https:\/\/doi.org\/10.1007\/s11926-021-01043-5. This review describes variations in the clinical presentation of axSpA across the world.","DOI":"10.1007\/s11926-021-01043-5"},{"key":"1068_CR11","first-page":"554","volume":"28","author":"S Hukuda","year":"2001","unstructured":"Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28:554\u20139.","journal-title":"J Rheumatol"},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.1780280107","volume":"28","author":"MA Khan","year":"1985","unstructured":"Khan MA, van der Linden SM, Kushner I, Valkenburg HA, Cats A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. Arthritis Rheum. 1985;28:40\u20133. https:\/\/doi.org\/10.1002\/art.1780280107.","journal-title":"Arthritis Rheum"},{"key":"1068_CR13","doi-asserted-by":"publisher","unstructured":"\u2022 Kishimoto M, Yoshida K, Ichikawa N, Inoue H, Kaneko Y, Kawasaki T, et al. Clinical characteristics of patients with spondyloarthritis in Japan in comparison with other regions of the world. J Rheumatol. 2019;46:896\u2013903. https:\/\/doi.org\/10.3899\/jrheum.180412. This study elucidated clinical characteristics of patients with SpA in Japan compared to that in other areas of the world.","DOI":"10.3899\/jrheum.180412"},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","volume":"78","author":"A Boel","year":"2019","unstructured":"Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019;78:1545\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215707.","journal-title":"Ann Rheum Dis"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777\u201383. https:\/\/doi.org\/10.1136\/ard.2009.108233.","journal-title":"Ann Rheum Dis"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"e001752","DOI":"10.1136\/rmdopen-2021-001752","volume":"7","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Ono K, Fukui S, Kawaai S, Deshpande GA, Yoshida K, et al. Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open. 2021;7:e001752.","journal-title":"RMD Open."},{"key":"1068_CR17","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Matsubara Y, Nakamura Y, Tamura N, Kameda H, Otomo K, Kishimoto M, et al. A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan. Mod Rheumatol. 2021. https:\/\/doi.org\/10.1093\/mr\/roab096. This is a recent nationwide survey of SpA conducted in 2,221 randomly selected medical facilities in Japan.","DOI":"10.1093\/mr\/roab096"},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3109\/14397595.2015.1088679","volume":"26","author":"Y Nakashima","year":"2016","unstructured":"Nakashima Y, Ohishi M, Okazaki K, Fukushi J, Oyamada A, Hara D, et al. Delayed diagnosis of ankylosing spondylitis in a Japanese population. Mod Rheumatol. 2016;26:421\u20135. https:\/\/doi.org\/10.3109\/14397595.2015.1088679.","journal-title":"Mod Rheumatol"},{"key":"1068_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108","volume":"5","author":"C L\u00f3pez-Medina","year":"2019","unstructured":"L\u00f3pez-Medina C, Ramiro S, van der Heijde D, Sieper J, Dougados M, Molto A. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5: e001108. https:\/\/doi.org\/10.1136\/rmdopen-2019-001108.","journal-title":"RMD Open"},{"key":"1068_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014431","volume":"98","author":"Y Endo","year":"2019","unstructured":"Endo Y, Fujikawa K, Koga T, Mizokami A, Mine M, Tsukada T, et al. Characteristics of late-onset spondyloarthritis in Japan: a retrospective cohort study. Medicine. 2019;98: e14431. https:\/\/doi.org\/10.1097\/MD.0000000000014431.","journal-title":"Medicine"},{"key":"1068_CR21","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1093\/rheumatology\/keaa922","volume":"60","author":"T Sugihara","year":"2021","unstructured":"Sugihara T, Ishizaki T, Onoguchi W, Baba H, Matsumoto T, Iga S, et al. Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study. Rheumatology (Oxford). 2021;60:4252\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/keaa922.","journal-title":"Rheumatology (Oxford)"},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/14397595.2020.1775927","volume":"31","author":"T Tomita","year":"2021","unstructured":"Tomita T, Sato M, Esterberg E, Parikh RC, Hagimori K, Nakajo K. Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: a hospital claims database analysis. Mod Rheumatol. 2021;31:431\u201341. https:\/\/doi.org\/10.1080\/14397595.2020.1775927.","journal-title":"Mod Rheumatol"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/14397595.2021.1886629","volume":"31","author":"K Inui","year":"2021","unstructured":"Inui K, Sato M, Esterberg E, Parikh RC, Kimura S, Torisu-Itakura H. Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis. Mod Rheumatol. 2021;31:1179\u201391. https:\/\/doi.org\/10.1080\/14397595.2021.1886629.","journal-title":"Mod Rheumatol"},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3899\/jrheum.130959","volume":"42","author":"J Braun","year":"2015","unstructured":"Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J. Classification and diagnosis of axial spondyloarthritis \u2013 what is the clinically relevant difference? J Rheumatol. 2015;42:31\u20138. https:\/\/doi.org\/10.3899\/jrheum.130959.","journal-title":"J Rheumatol"},{"key":"1068_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","volume":"75","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Strand V, Kay J, Braun J. The term \u201cnon-radiographic axial spondyloarthritis\u201d is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75:791\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208852.","journal-title":"Ann Rheum Dis"},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3899\/jrheum.141598","volume":"42","author":"Y Ohara","year":"2015","unstructured":"Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, et al. Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol. 2015;42:1439\u201342. https:\/\/doi.org\/10.3899\/jrheum.141598.","journal-title":"J Rheumatol"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3109\/14397595.2014.964925","volume":"25","author":"K Kamo","year":"2015","unstructured":"Kamo K, Shuto T, Haraguchi A. Prevalence of spondyloarthritis symptom in inflammatory bowel disease patients: a questionnaire survey. Mod Rheumatol. 2015;25:435\u20137. https:\/\/doi.org\/10.3109\/14397595.2014.964925.","journal-title":"Mod Rheumatol"},{"key":"1068_CR28","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kameda H, Kobayashi S, Tamura N, Kadono Y, Tada K, Yamamura M, et al. Non-radiographic axial spondyloarthritis. Mod Rheumatol. 2021;31:277\u201382. https:\/\/doi.org\/10.1080\/14397595.2020.1830512. This review introduced diagnostic guidance for nr-axSpA in Japan.","DOI":"10.1080\/14397595.2020.1830512"},{"key":"1068_CR29","doi-asserted-by":"publisher","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria. Arthritis Rheum. 1984;27:361\u20138. https:\/\/doi.org\/10.1002\/art.1780270401","DOI":"10.1002\/art.1780270401"},{"key":"1068_CR30","doi-asserted-by":"publisher","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of spondyloarthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68;Suppl 2:ii1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018","DOI":"10.1136\/ard.2008.104018"},{"key":"1068_CR31","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1001\/jama.1977.03270510035017","volume":"237","author":"A Calin","year":"1977","unstructured":"Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977;237:2613\u20134.","journal-title":"JAMA"},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.21619","volume":"54","author":"M Rudwaleit","year":"2006","unstructured":"Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006;54:569\u201378. https:\/\/doi.org\/10.1002\/art.21619.","journal-title":"Arthritis Rheum"},{"key":"1068_CR33","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RGW Lambert","year":"2016","unstructured":"Lambert RGW, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis. 2016;75:1958\u201363. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208642.","journal-title":"Ann Rheum Dis"},{"key":"1068_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/14397595.2016.1176635","volume":"27","author":"S Kobayashi","year":"2017","unstructured":"Kobayashi S, Yoshinari T. A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis. Mod Rheumatol. 2017;27:142\u20139. https:\/\/doi.org\/10.1080\/14397595.2016.1176635.","journal-title":"Mod Rheumatol"},{"key":"1068_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10165-011-0557-x","volume":"22","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi S, Harigai M, Mozaffarian N, Pangan AL, Sharma S, Brown LS, et al. A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Mod Rheumatol. 2012;22:589\u201397. https:\/\/doi.org\/10.1007\/s10165-011-0557-x.","journal-title":"Mod Rheumatol"},{"key":"1068_CR36","doi-asserted-by":"publisher","unstructured":"Miyasaka N, CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252\u201362. https:\/\/doi.org\/10.1007\/s10165-008-0045-0","DOI":"10.1007\/s10165-008-0045-0"},{"key":"1068_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/14397595.2018.1525024","volume":"29","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Kashiwagi T, Kimura J. Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan. Mod Rheumatol. 2019;29:1007\u201312. https:\/\/doi.org\/10.1080\/14397595.2018.1525024.","journal-title":"Mod Rheumatol"},{"key":"1068_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/14397595.2018.1538004","volume":"30","author":"M Kishimoto","year":"2020","unstructured":"Kishimoto M, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, et al. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Mod Rheumatol. 2020;30:132\u201340. https:\/\/doi.org\/10.1080\/14397595.2018.1538004.","journal-title":"Mod Rheumatol"},{"key":"1068_CR39","doi-asserted-by":"publisher","unstructured":"Machado PM, Landew\u00e9 R, van der Heijde DV, Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77:1539\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213184","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"1068_CR40","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1093\/rheumatology\/keaa829","volume":"60","author":"T Makino","year":"2021","unstructured":"Makino T, Ihn H, Nakagawa M, Urano M, Okuyama R, Katoh N, et al. Effect of adalimumab on axial manifestations in Japanese patients with psoriatic arthritis: a 24 week prospective, observational study. Rheumatology (Oxford). 2021;60:3669\u201378. https:\/\/doi.org\/10.1093\/rheumatology\/keaa829.","journal-title":"Rheumatology (Oxford)"},{"key":"1068_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1346-8138.15655","volume":"48","author":"H Fujita","year":"2021","unstructured":"Fujita H, Ohtsuki M, Morita A, Nagao R, Seko N, Matsumoto K, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan. J Dermatol. 2021;48:175\u201383. https:\/\/doi.org\/10.1111\/1346-8138.15655.","journal-title":"J Dermatol"},{"key":"1068_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221422","author":"J Braun","year":"2021","unstructured":"Braun J, Landew\u00e9 RB. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u2018physician-reported spondylitis\u2019? Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221422.","journal-title":"Ann Rheum Dis"},{"key":"1068_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/1346-8138.14097","volume":"45","author":"T Yamamoto","year":"2018","unstructured":"Yamamoto T, Kawada A. Clinical characteristics of Japanese patients with psoriatic arthritis: comparison with East Asian countries. J Dermatol. 2018;45:273\u20138. https:\/\/doi.org\/10.1111\/1346-8138.14097.","journal-title":"J Dermatol"},{"key":"1068_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12325-018-0866-y","volume":"36","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Tanaka Y, Sano S, Kameda H, Taniguchi A, Kashiwagi T, et al. Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis. Adv Ther. 2019;36:691\u2013707. https:\/\/doi.org\/10.1007\/s12325-018-0866-y.","journal-title":"Adv Ther"},{"key":"1068_CR45","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/1346-8138.15924","volume":"48","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T, Ohtsuki M, Kawada A. Early psoriatic arthritis in Japan: post-hoc analyses from a survey by the Japanese Society of Psoriasis Research. J Dermatol. 2021;48:902\u20136. https:\/\/doi.org\/10.1111\/1346-8138.15924.","journal-title":"J Dermatol"},{"key":"1068_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245954","volume":"16","author":"M Okada","year":"2021","unstructured":"Okada M, Kurimoto S, Ganz F, Boehncke WH. LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: subgroup analysis results from Japan. PLoS ONE. 2021;16: e0245954. https:\/\/doi.org\/10.1371\/journal.pone.0245954.","journal-title":"PLoS ONE"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01068-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T05:23:54Z","timestamp":1651728234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01068-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01068-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"7 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H. Kameda has received consulting fees, speaking fees, and\/or honoraria from AbbVie G.K., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, and Novartis Pharma K.K., and has received research grants from AbbVie G.K., Eisai Co., Ltd., and Mitsubishi Tanabe Pharma.M. Kishimoto has received consulting fees and\/or speaker fees from AbbVie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Novartis, Tanabe-Mitsubishi, and UCB Pharma.S. Kobayashi has received consulting fees and\/or speaker fees from Kyowa Kirin Co., Ltd, Novartis Pharma K.K., Eli Lilly Japan K.K., Chugai Parma, Asahi-Kasei Pharma, Gilead Sciences Inc., and Janssen Pharmaceutical K.K.T. Tomita has received consultancy and speaker fees from AbbVie, Astellas, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, Janssen, Kyowa Kirin, Mitsubishi-Tanabe, Novartis, and Pfizer.A. Morita has received research grants, consulting fees, and\/or speaker\u2019s fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun Pharmaceutical Industries Taiho Pharmaceutical, Torii Pharmaceutical, Ushio, and UCB Pharma.M. Yamamura has received consulting fees, speaking fees, and\/or honoraria from Eli Lilly Japan K.K., and Novartis Pharma K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}